Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 8Triple Negative Breast Neoplasms 4Carcinoma, Adenoid Cystic 2Resectable HER2-positive Breast Cancer 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Non-Muscle Invasive Bladder Neoplasms 1Neoplastic Cells, Circulating 1Neoplasms 1Lymphoma, B-Cell, Marginal Zone 1Inflammatory Breast Neoplasms 1Down Syndrome 1

Interventions

Vincristine 3Methotrexate 3Mercaptopurine 3Cytarabine 3Cyclophosphamide 3prednylidene 2pegaspargase 2merphos 2dexamethasone acetate 2dexamethasone 21-phosphate 2azathiopurine 2auricularum 2Thioguanine 2Prednisolone 2Leucovorin 2Doxorubicin 2Dexamethasone 2Calcium Dobesilate 2deltacortene 1blinatumomab 1asparaginase erwinia chrysanthemi recombinant 1Radiotherapy 1Radiation 1Prednisone 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Methylprednisolone 1Hydrocortisone 1Epirubicin 1Daunorubicin 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Down Syndrome × Epirubicin × 90 days × Clear all
NCT03286634 2026-05-11

ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016

National Hospital Organization Nagoya Medical Center

Phase 2 Active not recruiting
60 enrolled
LymphoidOther hematologic neoplasm

Down Syndrome, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡